AROCELL AB (PUBL) Inactive Instrument
AroCell AB (publ) Stock Nasdaq Stockholm
Equities
SE0003883990
Biotechnology & Medical Research
| Sales 2024 * | 61M 5.6M | Sales 2025 * | 82.4M 7.56M | Capitalization | 84.08M 7.72M |
|---|---|---|---|---|---|
| Net income 2024 * | -51M -4.68M | Net income 2025 * | -32M -2.94M | EV / Sales 2024 * | 0.79 x |
| Net cash position 2024 * | 36M 3.3M | Net cash position 2025 * | 38M 3.49M | EV / Sales 2025 * | 0.56 x |
| P/E ratio 2024 * |
-1.83
x | P/E ratio 2025 * |
-3.65
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 44.36% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Anders Hultman
CEO | Chief Executive Officer | 50 | 18-11-30 |
Lars Jakobsson
DFI | Director of Finance/CFO | 67 | - |
Gustav Sten
COO | Chief Operating Officer | - | 18-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 65 | 21-12-31 | |
| Director/Board Member | 63 | 21-04-30 | |
Clas Runnberg
BRD | Director/Board Member | 72 | 22-12-31 |
AroCell publ AB is a Sweden-based diagnostic Company engaged in the development of markers for determination of cell growth (TK 210) and apoptosis. The Company's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company develops a marker for solid tumor cancer disease. The AroCell cooperates with partners within development, production and sales.
Calendar
2024-05-02
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +0.83% | 43.84B | |
| +6.22% | 41.68B | |
| +45.26% | 41.25B | |
| -11.96% | 27.04B | |
| +6.14% | 25.53B | |
| -24.32% | 18.18B | |
| -3.52% | 12.29B | |
| +26.15% | 12.29B | |
| +6.90% | 11.15B |
